Kangroo Mother Care

NCT ID: NCT05955404

Last Updated: 2023-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-02
• Study Completion Date: 2023-02-28

Brief Summary

infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs.

Detailed Description

infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs and comparing the pain intensity with preterm infants who receive conventional care.

Conditions

Preterm Birth Complication

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Kangaroo mother care

This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.

Group Type: EXPERIMENTAL

Kangaroo mother care

Intervention Type: OTHER

This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.

Interventions

Kangaroo mother care

This study uses the Kangaroo mother care as a non-pharmacological strategy to alleviate the pain that preterm infants experience in the NICU.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Preterm infants whose corrected gestational age from (32 - <37) weeks of pregnancy
• Preterm infants who do not experience any painful procedure for last 24 hours
• Preterm infants do not receive any sedation for last 24 hours

Exclusion Criteria

• full-term infants whose corrected gestational age is >37 weeks
• extremely preterm (< 28 weeks)
• very preterm (28-<32 weeks)
• proven or suspected sepsis
• major congenital malformations
• all heart defect except neonatal Patent ductus arteriosus (PDA)
• necrotizing enterocolitis
• neurodevelopmental disability
• who receive respiratory support {Mechanical Ventilation, Continuous Positive Airway Pressure, or high-flow support
• indicated for surgery
• contraindication to oral sucrose
• Twins
• infants had a condition that might influence their responses to pain, e.g., congenital anomalies or severe illnesses requiring treatment with antiepileptics, muscle relaxants, or analgesic drugs

• Minimum Eligible Age: 32 Weeks
• Maximum Eligible Age: 37 Weeks
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Baghdad

OTHER

Sponsor Role: lead

Responsible Party

Hiba Abdulwahid Dawood

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

College of Nursing- The University of Baghdad

Baghdad, , Iraq

Countries

Iraq

Other Identifiers

kangroo mother care

Identifier Type: -

Identifier Source: org_study_id